Online platform makes requesting, analyzing shared clinical trial data more accessible in hopes of accelerating vaccine and treatment research.
The science community now has free access to a COVID-19 research portal that launched today. Vivli, a global independent, nonprofit data-sharing and analytics platform for clinical trial research, with the help of
'Especially during this time of a public health emergency, data sharing is more important than ever,' said
To date, there are hundreds of trials currently being planned or ongoing. As results from those studies become available and researchers agree to share their results, Vivli will be updating the portal and listing those trials. Researchers can begin submitting requests through the COVID-19 portal, developed by Insight.
'It's exciting to be able to lend support to Vivli in their efforts to launch the COVID-19 portal,' said
Insight has been the nonprofit's long-standing technical development and maintenance partner, helping Vivli launch its global clinical trial research platform in 2018.
Researchers who would like to participate in sharing COVID-19-related research trial data can access the portal at https://vivli.org/vivli-covid-19-portal/.
About Vivli
Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit www.vivli.org and follow us on Twitter @VivliCenter.
About Insight
Today, every business is a technology business.
Tel. (480) 889-9798
Email: scott.walters@insight.com
Tel. (212) 446-1884
Email: akouvaras@sloanepr.com
(C) 2020 Electronic News Publishing, source